Pantarol (Pantoprazole)

Pantarol, a proton pump inhibitor, acts on the gastric acid‑secreting pathway to control hyperacidity disorders.

• Gastro‑oesophageal reflux disease (GERD): reduces acid exposure and improves heart‑burn symptoms.
• Erosive oesophagitis: promotes healing of inflamed oesophageal mucosa.
• Peptic ulcer disease: facilitates ulcer closure and prevents recurrence.
• Stress ulcer prophylaxis: lowers risk of gastric lesions in critically ill patients.

• Pantoprazole binds covalently to the H+/K+ ATPase (the gastric proton pump) on the secretory surface of parietal cells, irreversibly inhibiting its activity. This blockade prevents the final step of gastric acid secretion, leading to a sustained reduction in both basal and stimulated gastric acidity.

Adverse reactions may occur with any dosage form of pantoprazole.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: watery stools, usually transient.
• Nausea: occasional upset stomach.
• Abdominal pain: cramping or discomfort.
• Flatulence: increased gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with rash, swelling, and breathing difficulty.
• Clostridioides difficile infection: severe colitis presenting with watery diarrhoea.
• Hypomagnesemia: low serum magnesium causing muscle cramps or arrhythmia.
• Hepatic enzyme elevation: increased ALT/AST levels.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions.
• Cardiac arrhythmias: rare but potentially life‑threatening rhythm disturbances.

Before initiating therapy, consider the following safety measures.

• Renal impairment: monitor renal function and adjust therapy if needed.
• Hepatic impairment: use with caution; assess liver enzymes periodically.
• Pregnancy: Category B – discuss potential benefits and risks with the prescriber.
• Concomitant antiplatelet or anticoagulant therapy: monitor for increased bleeding risk.
• Long‑term use: evaluate the necessity regularly to avoid unnecessary exposure.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular events.
• Atazanavir: markedly decreased absorption, compromising antiviral efficacy.
• Warfarin: potential increase in INR, requiring closer anticoagulation monitoring.

Moderate Interactions (Monitor Closely)

• Methotrexate: increased serum levels, risk of toxicity.
• Digoxin: elevated concentrations, monitor for signs of digoxin toxicity.
• Phenytoin, carbamazepine, diazepam: possible reduction in plasma levels, consider dose adjustments.